Track Record

Since 2000 SynCo has assisted more than 50 companies with their process development, GMP manufacturing and aseptic filling needs, on route to the market. 

By selecting SynCo as your bulk drug substance and/or drug product contract manufacturing partner, you will benefit from over 11 years of biopharmaceutical manufacturing experience for both clinical and commercial supply of vaccines and biotherapeutics.

SynCo has been inspected and approved by both the Dutch regulatory authorities on behalf of EMA and foreign regulatory authorities, such as Korean FDA, Health Canada and ANVISA. SynCo also expects multiple US FDA Pre-Approval Inspections (PAIs) in the next 2-3 years for product launches onto the US market in 2012 to 2014.

Since its inception, SynCo has been a profitable business and has continued to increase its revenues in a sustainable way. This profitability allowed SynCo to invest and grow the company “to become the strategic manufacturing partner of choice”.